Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
Open Access
- 25 October 2012
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 3 (11) , 1335-1347
Abstract
Multiple Myeloma (MM) is an incurable malignant plasma cell disorder. We have evaluated the counts of Multiple Myeloma Cells (MMCs) and normal plasma cells (N-PCs), seven days after high-dose melphalan (HDM) and autologous stem transplantation (ASCT). Two third of patients had detectable minimal residual disease (MRD+) (71.7 MMCs/µL) after induction treatment with dexamethasone and proteasome inhibitor. MMC counts were reduced by 92% (P ≤ .05) but not eradicated 7 days after HDM+ASCT. Post-HDM+ASCT MMCs were viable and bathed in a burst of MMC growth factors, linked with post-HDM aplasia. In one third of patients (MRD- patients), MMCs were not detectable after induction treatment and remained undetectable after HDM+ASCT. Major difference between MRD- and MRD+ patients is that N-PC counts were increased 3 fold (P < .05) by HDM+ASCT in MRD- patients, but were unaffected in MRD+ patients. Possible explanation could be that clearance of MMCs in MRD- patients makes more niches available for N-PCs. Thus, MMCs are not fully eradicated shortly after HDM, are bathed in high concentrations of MMC growth factors in an almost desert BM, are viable in short-term culture, which suggests providing additional therapies shortly after HDM to kill resistant MMCs before full repair of lesions.Keywords
This publication has 40 references indexed in Scilit:
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myelomaBlood, 2012
- Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrowBlood, 2011
- Treatment of multiple myelomaNature Reviews Clinical Oncology, 2011
- Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple MyelomaJournal of Clinical Oncology, 2011
- Molecular Pathogenesis of Multiple Myeloma: Chromosomal Aberrations, Changes in Gene Expression, Cytokine Networks, and the Bone Marrow Microenvironment2011
- Epidemiology of Multiple Myeloma2011
- CD200 expression in plasma cell myelomaBritish Journal of Haematology, 2011
- Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myelomaLeukemia, 2011
- Mobilization of plasma cells in healthy individuals treated with granulocyte colony-stimulating factor for haematopoietic stem cell collectionImmunology, 2010
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple MyelomaClinical Cancer Research, 2008